Abstract
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to CytotherapyReferences
- Delivering cellular and gene therapies to patients: solutions for realizing the potential of the next generation of medicine.Gene Ther. 2020; 27: 537-544
Growth & Resilience in Regenerative Medicine—Annual Report - 2020, accessed 02 May 2021, < https://alliancerm.org/sector-report/2020-annual-report/>.
- Cost of goods is crucial for the future of regenerative medicine.BioProcess Int. 2019; 17: 12-17
- Challenges and opportunities in CAR T-Cell development and manufacturing.BioProcess Int. 2020; 18: 1-9
- The long road to affordability: a cost of goods analysis for an autologous CAR-T process.Cell Gene Ther Insights. 2018; 5: 177-196
- Cost analysis of vein-to-vein CAR T-cell therapy: automated manufacturing and supply chain.Cell Gene Ther Insights. 2020; 6: 487-510
- A roadmap for cost-of-goods planning to guide economic production of cell therapy products.Cytotherapy. 2017; 19: 1383-1391
Reed C. Recalibrating the Supply Chain For Allogenic Cell Therapies. 2019. Accessed May, 2021. https://www.cellandgene.com/doc/recalibrating-the-supply-chain-for-allogeneic-cell-therapies-0001.
O'Donnell D. The Cell Therapy Supply Chain: Logistical Considerations for Autologous Immunotherapies. 2015. Accessed May, 2021. https://bioprocessintl.com/manufacturing/cell-therapies/the-cell-therapy-supply-chain-logistical-considerations-for-autologous-immunotherapies/.
- CMC obstacles in cell and gene therapy: four solutions to solve six challenges.Cell & Gene Therapy Insights. 2021; 7: 471-488
U.S. Department of Health and Human Services. Food and Drug Administration. Center for Biologics Evaluation and Research. Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs). 2020. Accessed May 2021. https://www.fda.gov/media/113760/download.
European Commission. Guidelines of 22.11.2017 Good Manufacturing Practice for Advanced Therapy Medicinal Products. 2017. Accessed May 2021. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-4/2017_11_22_guidelines_gmp_for_atmps.pdf.
- Technical Considerations in the Freezing Low-Temperature Storage and Thawing of Stem Cells for Cellular Therapies.Transfus Med Hemother. 2019; 46: 134-149
- Transitioning from development to commercial: risk-based guidance for critical materials management in cell therapies.Cytotherapy. 2020 Nov; 22; : 669-676
- Off the shelf cellular therapeutics: Factors to consider during cryopreservation and storage of human cells for clinical use.Cytotherapy. 2016; 18: 697-711
- Packaging Considerations for Biopreservation.Transfus Med Hemother. 2011; 38: 149-156
Aseptic Technologies. Container Closure Integrity of the AT-Closed Vial® Stored at Cryogenic Temperatures Proven Using Non-Destructive Headspace Analysis. 2014:2. Accessed May 2021. http://www.aseptictech.com/sites/default/files/publications/at-closed_vial_container_closure_integrity_using_headspace_analysis.pdf.
Aseptic Technologies. Container Closure Integrity at Cryogenic Temperatures: How the AT-Closed Vial® ensures safe cryopreservation of novel therapies. 2020:6. Accessed May 2021. https://www.aseptictech.com/sites/default/files/publications/aseptic_technologies_press_release_at-closed_vial_technology_for_cryostored_cell_and_gene_therapy_products.pdf#:~:text=cryopreservation%20of%20novel%20therapies%2C%20validating%20that%20the%20company’s,technologies%2C%20equipment%2C%20and%20devices%20for%20the%20pharmaceutical%20industry.
- Decentralised manufacturing of cell and gene therapy products: Learning from other healthcare sectors.Biotech Advances. 2018; 36: p345-p357
Palmer E. China's Sanpower takes on expensive Provenge manufacturing with Dendreon deal. 2017. Accessed May 2021. https://www.fiercepharma.com/manufacturing/china-s-sanpower-takes-expensive-provenge-manufacturing-dendreon-deal.
- The long road to affordability: a cost of goods analysis for an autologous CAR-T process.Cell Gene Therapy Insights. 2018; (doi:10.18609): 1105-1118
International Organization for Standardization. ISO 21973:2020(E) Biotechnology — General requirements for transportation of cells for therapeutic use. 2020:19
